Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Goodwill & Intangibles (2016 - 2025)

Historic Goodwill & Intangibles for RedHill Biopharma (RDHL) over the last 15 years, with Q2 2025 value amounting to $5.5 million.

  • RedHill Biopharma's Goodwill & Intangibles fell 55.74% to $5.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was $5.5 million, marking a year-over-year decrease of 55.74%. This contributed to the annual value of $5.5 million for FY2024, which is 55.58% down from last year.
  • RedHill Biopharma's Goodwill & Intangibles amounted to $5.5 million in Q2 2025, which was down 55.74% from $5.5 million recorded in Q4 2024.
  • RedHill Biopharma's 5-year Goodwill & Intangibles high stood at $89.4 million for Q4 2021, and its period low was $5.5 million during Q2 2025.
  • For the 5-year period, RedHill Biopharma's Goodwill & Intangibles averaged around $47.9 million, with its median value being $67.9 million (2022).
  • As far as peak fluctuations go, RedHill Biopharma's Goodwill & Intangibles skyrocketed by 44288.06% in 2021, and later plummeted by 9375.87% in 2023.
  • Over the past 5 years, RedHill Biopharma's Goodwill & Intangibles (Quarter) stood at $89.4 million in 2021, then changed by 0.0% to $89.4 million in 2022, then tumbled by 93.76% to $5.6 million in 2023, then dropped by 0.56% to $5.5 million in 2024, then dropped by 0.29% to $5.5 million in 2025.
  • Its last three reported values are $5.5 million in Q2 2025, $5.5 million for Q4 2024, and $5.6 million during Q2 2024.